NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

April 6, 2021

Study Completion Date

April 6, 2021

Conditions

Pneumonia

Interventions

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.

BIOLOGICAL

pneumococcal vaccine polyvalent

This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.

Trial Locations (1)

Unknown

Qi County Center for Disease Control and Prevention, Hebi

All Listed Sponsors

collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

Ab&B Bio-tech Co., Ltd.JS

OTHER